Perseus Proteomics (4882) · RiskFirst stated

Stagnation in the Growth of the Antibody Drug Market Due to Small-Molecule, Medium-Molecule and Nucleic Acid Drugs, and Regenerative Medicine and Cell Therapy

First written in FY2026. . Latest entry: FY2026.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Risk of Stagnation in Antibody Therapeutics Market Growth and Competition from Other ModalitiesA theme 3 companies write about · 3 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2026First statedAnnual report
「Based on data and forecasts indicating trends in the pharmaceutical industry, we expect the antibody drug market to grow steadily. However, if the antibody drug market does not expand as expected due to the development and advancement of competing modalities, including small-molecule drugs, mid-sized molecule drugs, nucleic acid drugs, and regenerative and cell therapies, this could affect our operating results and financial position.」
In addition to the existing risk from competing new drugs, we separately disclosed the risk that the antibody drug market may not expand as expected due to the development of small-molecule, mid-sized molecule and nucleic acid drugs, as well as regenerative and cell therapies.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Perseus Proteomics yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.